1 Multimodal analysis of methylomics and fragmentomics in plasma cell-free

2 **DNA for multi-cancer early detection and localization**

Van Thien Chi Nguyen^{1,2#}, Trong Hieu Nguyen^{1,2#}, Nhu Nhat Tan Doan^{1,2}, Thi Mong Quynh 3 Pham^{1,2}, Giang Thi Huong Nguyen^{1,2}, Thanh Dat Nguyen^{1,2}, Thuy Thi Thu Tran^{1,2}, Duy Long Vo³, 4 5 Thanh Hai Phan⁴, Thanh Xuan Jasmine⁴, Van Chu Nguyen^{5,6}, Huu Thinh Nguyen³, Trieu Vu Nguyen⁷, Thi Hue Hanh Nguyen^{1,2}, Le Anh Khoa Huynh^{1,8}, Trung Hieu Tran^{1,2}, Ouang Thong 6 Dang³, Thuy Nguyen Doan³, Anh Minh Tran³, Viet Hai Nguyen³, Vu Tuan Anh Nguyen³, Le 7 Minh Quoc Ho³, Quang Dat Tran³, Thi Thu Thuy Pham⁴, Tan Dat Ho⁴, Bao Toan Nguyen⁴, 8 Thanh Nhan Vo Nguyen⁴, Thanh Dang Nguyen⁴, Dung Thai Bieu Phu⁴, Boi Hoan Huu Phan⁴, Thi 9 Loan Vo⁴, Thi Huong Thoang Nai⁴, Thuy Trang Tran⁴, My Hoang Truong⁴, Ngan Chau Tran⁴, 10 Trung Kien Le³, Thanh Huong Thi Tran^{5,6}, Minh Long Duong^{5,6}, Hoai Phuong Thi Bach^{5,6}, Van 11 Vu Kim^{5,6}, The Anh Pham^{5,6}, Duc Huy Tran³, Trinh Ngoc An Le³, Truong Vinh Ngoc Pham³, 12 13 Minh Triet Le³, Dac Ho Vo^{1,2}, Thi Minh Thu Tran^{1,2}, Minh Nguyen Nguyen^{1,2}, Thi Tuong Vi Van^{1,2}, Anh Nhu Nguyen^{1,2}, Thi Trang Tran^{1,2}, Vu Uyen Tran^{1,2}, Minh Phong Le^{1,2}, Thi Thanh 14 Do^{1,2}, Thi Van Phan^{1,2}, Luu Hong Dang Nguyen^{1,2}, Duy Sinh Nguyen^{1,2}, Van Thinh Cao⁹, Thanh 15 16 Thuy Thi Do², Dinh Kiet Truong², Hung Sang Tang^{1,2}, Hoa Giang^{1,2}, Hoai Nghia Nguyen^{1,2}, Minh Duy Phan^{1,2,*}, Le Son Tran^{1,2,*} 17

- 18
- ¹Gene Solutions, Ho Chi Minh City, Vietnam
- ²Medical Genetics Institute, Ho Chi Minh City, Vietnam
- ³University Medical Center, Ho Chi Minh City, Vietnam
- ⁴MEDIC Medical Center, Ho Chi Minh City, Vietnam
- ⁵National Cancer Hospital, Hanoi, Vietnam

⁶Hanoi Medical University, Hanoi, Vietnam

25	⁷ Thu Duc City Hospital, Ho Chi Minh City, Vietnam								
26	⁸ Department of Biostatistics, Virginia Commonwealth University, School of Medicine,								
27	Richmond, VA, USA								
28	⁹ Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam								
29									
30									
31									
32									
33									
34									
35									
36	# Van Thien Chi Nguyen and Trong-Hieu Nguyen contributed equally to this study.								
37	*Correspondence: pmduy@yahoo.com; leson1808@gmail.com								
38									
39									
40	Key words: liquid biopsy, multimodal analysis, methylation, fragment length, cell-free DNA,								
41	circulating tumor DNA, multicancer early detection, tissue of origin, machine learning, graph								
42	convolutional neutral network.								

43

24

45 Abstract

46 Despite their promise, circulating tumor DNA (ctDNA)-based assays for multi-cancer early 47 detection face challenges in test performance, due mostly to the limited abundance of ctDNA and 48 its inherent variability. To address these challenges, published assays to date demanded a very high-depth sequencing, resulting in an elevated price of test. Herein, we developed a multimodal 49 50 assay called SPOT-MAS (Screening for the Presence Of Tumor by Methylation And Size) to 51 simultaneously profile methylomics, fragmentomics, copy number, and end motifs in a single 52 workflow using targeted and shallow genome-wide sequencing (~0.55X) of cell-free DNA. We 53 applied SPOT-MAS to 738 nonmetastatic patients with breast, colorectal, gastric, lung and liver 54 cancer, and 1,550 healthy controls. We then employed machine learning to extract multiple cancer and tissue-specific signatures for detecting and locating cancer. SPOT-MAS successfully 55 56 detected the five cancer types with a sensitivity of 72.4% at 97.0% specificity. The sensitivities for detecting early-stage cancers were 62.3% and 73.9% for stage I and II, respectively, 57 increasing to 88.3% for nonmetastatic stage IIIA. For tumor-of-origin, our assay achieved an 58 59 accuracy of 0.7. Our study demonstrates comparable performance to other ctDNA-based assays 60 while requiring significantly lower sequencing depth, making it economically feasible for 61 population-wide screening.

62 Introduction

63 The incidence of cancer-related morbidity and mortality is rapidly increasing globally, and 64 accounted for nearly one fifth of all deaths in 2020 (1). High-cost treatment is a significant 65 financial burden for cancer patients, with almost 286 billion dollars in 2021 and an increase of 8.2% to 581 billion dollars in 2030. In Vietnam, GLOBOCAN 2020 reported over 182,500 66 67 newly diagnosed cases and 122,690 cancer-related deaths (1). Among these, liver (14.5%), lung (14.4%), breast (11.8%), gastric (9.8%), and colorectal cancer (9%) are the five most common 68 types. Up to 80% of cancer patients in Vietnam were diagnosed at stage III or stage IV, resulting 69 70 in a high rate of 1-year mortality (25%) and a low 5-year survival rate compared to other 71 countries (2). Diagnostic delays are associated with a lower chance of survival, greater treatment-associated problems, and higher costs (3). Cancer detection at earlier stages can 72 73 improve the opportunity to control cancer progression, increase the patient survival rate, and 74 lower medical expenses (4).

75 Most current early cancer screening assays have limitations such as invasiveness, low 76 accessibility, and high false positive rates when used sequentially, resulting in overdiagnosis and 77 overtreatment. Multi-cancer early detection (MCED) tests can potentially overcome these 78 challenges by simultaneously detecting multiple cancer types from a single test (5). Liquid 79 biopsy, an emerging non-invasive approach for MCED, can capture a wide range of tumor features, including cell free DNA (cfDNA), circulating tumor DNA (ctDNA), exosomes, 80 proteins, mRNA, and metabolites (6, 7). Among them, ctDNA has become a promising 81 biomarker for detecting early-stage cancers because it is a carrier of genetic and epigenetic 82 83 modifications from cancer-derived DNA (8). Indeed, ctDNA detection has demonstrated several advantages in non-invasive diagnostic, prognostic, and monitoring of cancer patients during and 84

after treatment (9, 10). Furthermore, ctDNA carrying tumor-specific alterations could be used to
identify the corresponding unknown primary cancer and tumor localization.

87 In recent years, there has been considerable interest in exploring the potential of ctDNA 88 alterations for early detection of cancer and localization of the tissue of origin (TOO) (11, 12). One such approach is the PanSeer test, which uses 477 differentially methylated regions (DMRs) 89 90 in ctDNA to detect five different types of cancer up to four years prior to conventional diagnosis 91 (13). However, this assay is limited in its ability to determine the TOO, as it only uses methylation regions common to multiple cancers. The DELFI assay employs a genome-wide 92 93 analysis of ctDNA fragment profiles to increase sensitivity in early detection, but also lacks 94 accuracy in classifying the source of tumor-derived cfDNA (14). Recently, the Galleri test has 95 emerged as a multi-cancer detection assay that analyses more than 100,000 methylation regions 96 in the genome to detect over 50 cancer types and localize the tumor site (15). This approach requires a large-scale target capture panel at very high-depth sequencing (with a depth coverage 97 98 of 30X), incurring high sequencing costs and limiting the accessibility of this test to the wider 99 population.

Despite their great potential, there remain several challenges that these assays must solve to 100 101 deliver accessible and reliable clinical adoption for the large population, including the low fraction of ctDNA in the blood of early stage cancer patients, the heterogeneity of ctDNA 102 signatures from diverse cancer types, subtypes and stages (16), and the high sequencing depth 103 required. To address these challenges, recent studies have focused on multi-analyte approach -104 105 combining genomic and nongenomic features such as methylomics and fragmentomics to 106 increase the detection of ctDNA and accuracy for TOO identification (16-18). Advances in multimodal analysis approaches have led to the development of powerful screening tests that 107

108 enable high sensitivity and cost-effectiveness. For example, CancerSEEK uses a combined 109 approach of protein biomarkers and genetic alterations to detect and locate the presence of eight 110 types of cancers (19). In this assay, cancer-associated serum proteins play a complementary role 111 in tumor localization as cfDNA mutations are not tissue specific. However, detecting both protein and genetic biomarkers are time-consuming and costly. Thus, the development of future 112 MCED tests should endeavor to deliver a screening approach with high sensitivity, specificity, 113 and TOO identification at cost-effective price to provide better clinical outcomes and treatment 114 opportunities for all cancer patients. 115

116 In an effort to address the challenges of early cancer detection, we have developed a multimodal 117 approach called SPOT-MAS (Screening for the Presence Of Tumor by DNA Methylation And Size). This assay was previously applied to cohorts of colorectal (20) and breast cancer (under 118 119 review in Frontiers in Oncology) patients and demonstrated ability for early detection of these 120 cancers at high sensitivity across different cancer stages and patient age groups. In this study, we expanded our multimodal approach, SPOT-MAS to comprehensively analyze methylomics, 121 122 fragmentomics, DNA copy number and end motifs of cfDNA for simultaneously detecting and 123 locating cancer from a single screening test. As proof of concept, we used 2,288 participants, 124 including 738 nonmetastatic patients and 1,550 healthy controls, to train and fully validate this approach on five commonly diagnosed cancers, including breast, gastric, lung, colorectal, and 125 liver cancer. These cancer types accounted for more than 54% of new cancer cases and 57% of 126 127 cancer death worldwide as well as the most diagnosed cancer types in developing counties (1, 2). By using targeted sequencing, shallow whole genome sequencing (with a depth coverage of 128 0.55X) and innovative machine learning algorithms, we could analyze a large multi-feature 129 130 datasets of cfDNA for multi-cancer early detection and tumor localization with high sensitivity

and cost-effectiveness. Our assay achieved sensitivities of early detection of 72.4% among the five cancer types at specificity of 97.0%, with AUC of 0.95. Moreover, we could identify the tissue of origin with an accuracy of 0.7 in independent validation cohort using graph convolutional neural network. Thus, SPOT-MAS has the potential to become a universal, simple, and cost-effective approach for early multi-cancer detection in large populations.

136 Methods

137 **Patient enrollment**

138 This study recruited 738 cancer patients (223 breast cancer, 159 CRC, 122 liver cancer, 136 lung cancer, 98 gastric cancer) and 1550 healthy subjects. All cancer patients were confirmed to have 139 140 one of the five cancers analyzed in this study. Cancer stages were determined following guidelines from the American Joint Committee on Cancer and the International Union for Cancer 141 142 Control (21). Individuals were considered healthy if they had no history of cancer at the time of enrollment and follow-up interviews were conducted by specialized physicians to confirm 143 noncancer status at 6 and 12 months after enrollment. Study subjects were recruited from the 144 145 University Medical Center, Thu Duc City Hospital, University of Medicine and Pharmacy, Medic Medical Center and Medical Genetics Institute in Ho Chi Minh city, Vietnam, National 146 Cancer Hospital and Hanoi Medical University in Hanoi from May 2019 to December 2022. 147

Written informed consent was obtained from each participant in accordance with the Declaration
of Helsinki. This study was approved by the Ethics Committee of the Medic Medical Center,
University of Medicine and Pharmacy and Medical Genetics Institute, Ho Chi Minh city,
Vietnam. All cancer patients were treatment-naïve at the time of blood sample collection.

152 Isolation of cfDNA

10 mL of blood was collected from each participant in a Cell-Free DNA BCT tube (Streck, USA). Plasma was collected from blood samples after centrifugation with two rounds (2,000 × g for 10 min and then 16,000 × g for 10 min). The plasma fraction was aliquoted for long-term storage at -80 °C. Cell free DNA (cfDNA) was extracted from 1 mL plasma aliquots using the MagMAX Cell-Free DNA Isolation kit (ThermoFisher, USA), according to the manufacturer's instructions. Extracted cfDNA was quantified by the QuantiFluor dsDNA system (Promega, USA).

160 **Bisulfite conversion and library preparation**

According to the manufacturer's instructions, bisulfite conversion and cfDNA purification were prepared by EZ DNA Methylation-Gold Kit (Zymo research, D5006, USA). DNA library was prepared from bisulfite-converted DNA samples using xGenTM Methyl-Seq DNA Library Prep Kit (Integrated DNA Technologies, 10009824, USA) with AdaptaseTM technology, according to the manufacture's instructions. The QuantiFlour dsDNA system (Promega, USA) was used to analyse the concentration of DNA.

167 Target region capture, whole genome hybridization & sequencing

DNA from library products were pooled equally, hybridized and captured using The XGen 168 169 hybridization and wash kit (Integrated DNA Technologies, 1072281, USA), together with our customized panel of xGen Lockdown Probes including 450 regions across 18,000 CpG sites 170 (Integrated DNA Technologies, USA). The construction of panel was built as previously 171 172 described (13, 20, 22). After hybridization, the flow-through product was concentrated using 173 SpeedVac (N-Biotek, NB-503CIR, Korea) at 65°C. The samples were then added with the 174 hybridization master mixture (hybridization buffer, hybridization enhancer and H_2O) and denatured. Biotinylated P5 and P7 probes (P5-biotin: /5Biosg/AATGATACGGCGACCACCGA, 175

176 P7-biotin: /5Biosg/CAAGCAGA AGACGGCATACGAGAT) on streptavidin magnetic beads 177 (Invitrogen, CA, USA) were hybridized with the single-stranded DNA. The captured DNA products were amplified by a PCR reaction with free P5 and P7 primers (P5 primer: 178 179 AATGATACGGCGACCACCGA, P7 primer: CAAGCAGAAGACGGCATACGA). The concentrations of DNA libraries were determined using the QuantiFluor dsDNA system 180 (Promega, USA). Both target and flow-through fraction were sequenced on the DNBSEQ-G400 181 DNA system (MGI Tech, Shenzhen, China) with 100-bp paired-end reads at a sequencing depth 182 of 20 million reads per fraction. Data was demultiplexed by bcl2fastq (Illumina, CA, USA). 183 184 FASTQ files were then examined using FastQC v. 0.11.9 and MultiQC v. 1.12.

Targeted methylation analysis (TM)

All paired-end reads were processed by Trimmomatic v 0.32 with the option HEADCROP. The trimmed reads were then aligned by Bismark v. 0.22.3. Deduplication and sorting of BAM files were conducted using Samtools v. 1.15. Reads falling into our 450 target regions were filtered using Bedtools v. 2.28. Methylation calling was performed using Bismark methylation extractor (20). Briefly, methylation ratio was measured for each target region:

191
$$Methylation ratio = \frac{methylated cyto sin e(C)}{methylated C + unmethylated C}$$

192 Methylation fold change from cancer to control was calculated for each target region. For 193 analyzing differential methylated regions, significance level was set at $p \le 0.05$, corresponding to 194 a -log10 adjusted p-value ≥ 1.301 (Benjamini-Hochberg correction).

195 **Genome-wide methylation analysis (GWM)**

196 The integrated bioinformatics pipeline Methy-pipen was used to analyse GWM. We carried out 197 the trimming step using Trimmomatic, removing adapter sequence and low-quality bases at 198 fragment ends (20). The methylation ratio for each bin was calculated as following equation.

199
$$Methylation ratio = \frac{methylated cyto sin e(C)}{methylated C + unmethylated C}$$

Mean methylation ratio was calculated for each bin and subsequently used to plot GWM density curves. To identify bins with significant methylation changes between cancer and control group, methylation ratio in each bin of cancer samples were compared with corresponding values in control samples using Wilcoxon rank sum test. Bins with adjusted p-value (Benjamini-Hochberg correction) ≤ 0.05 were considered significant. Those with log₂ fold change (cancer vs control) > 0 were categorized as hypermethylated bins. Those with log₂ fold change (cancer vs control) < 0 were categorized as hypermethylated bins.

207 Copy number aberration analysis (CNA)

208 CNA analysis was performed using the R-package QDNAseq (23). We also used 1-Mb 209 segmetation strategy to analyse CNA. We excluded bins that felt into the low mappability and 210 Duke blacklist regions(24). The number of reads mapped to each bin was measured by the 211 function "binReadCounts", and GC-content correction was conducted by the functions 212 "estimateCorrection" and "correctBins". The final CNA feature was derived by bin-wise 213 normalizing and outlier smoothing with the functions "normalizeBins" and "smoothOutlierBins". 214 This process resulted in a feature vector of a length of 2691 bins.

To identify significant DNA gain or loss between cancer and control group, CNA values in each bin of cancer samples were compared with corresponding values in control samples using Wilcoxon rank sum test. Bins with adjusted p-value (Benjamini-Hochberg correction) ≤ 0.05

were considered significant. Those with \log_2 fold change (cancer vs control) > 0 were categorized as significant increase. Those with \log_2 fold change (cancer vs control) < 0 were categorized as significant decrease.

221 Fragment length analysis (FLEN, SHORT, LONG, TOTAL, RATIO)

We used an in-house python script to convert the balign files into BAM files and collected the fragment length from 100 to 250 bp, resulting in 151 possible fragment lengths for further analysis. The fragment frequency in each length (%) was measured by getting the proportion of reads with that length to the total read count in the range of 100 to 250 bp. Fragment length (bp) against fragment frequency (%) was plotted to obtain a FLEN distribution curve.

We divided the whole genome into 588 non-overlapping bins of 5Mb (5 million bases) long and then extracted the read counts regarding these bins. Short fragments have lengths from 100 to 150 bp and long fragments have lengths from 151 to 250 bp. The ratio of short and long fragments was calculated by dividing the number of each fragment. All the short, long and total read counts for each sample in 588 bins were normalized using z-score normalization. The short, long and total normalized read counts and short/long ratios were chosen as features analyzed (SHORT, LONG, TOTAL, RATIO).

234 End motif analysis (EM)

AdaptaseTM technology (Integrated DNA Technologies, USA) was used during library preparation to ligate adapters to ssDNA fragments in a template-independent reaction (25). This step involved adding a random tail to the 5' end of reverse reads. Although median length of the tail was 8 bp and thus allowed trimming to obtain information for other analysis, the randomlength tails did not allow exact determination of the 5' end of the reverse reads. Therefore, EM

features were determined based on the genomic coordinate of the 5' end of the forward reads. We determined the first 4-mer sequence based on the human reference genome hg19. In 256 possible 4-mer motifs, the frequency of each motif was calculated by dividing the number of reads carrying that motif by the total number of reads, generating an EM feature vector of a length of 256 for each sample.

245 Construction of machine learning models

All samples in the discovery cohort were used for model training to classify if a sample is 246 247 cancerous or not. For every feature type (TM, GWM, CNA, FLEN, SHORT, LONG, TOTAL, 248 RATIO and EM), three machine learning algorithms, including Logistic regression (LR), 249 Random Forest (RF) and Extreme Gradient Boosting (XGB), were applied. By using the 250 "GridSearchCV" function in the scikit-learn (v.1.0.2), model hyperparameters with the best 251 performance were chosen with 'CV' parameter (cross-validation) set to 5. The best 252 hyperparameters for each algorithm were found using function 'best_params_' implemented in 253 GridSearchCV. Subsequently, feature selection was performed for each algorithm as follows: (1) 254 for LR, the "penalty" parameter with '11' (LASSO regression), '12' (Ridge regression) and 'none' (no penalty) were examined to select the setting with the best performance; (2) for RF and 255 256 XGB, a "SelectFromModel" function with the 'threshold' was set at 0.0001 to get all features. 257 Then, the three algorithms (LR, RF, XGB) trained with the best hyperparameters and selected features were validated using k-fold cross validation approach on the dataset of training cohort 258 259 with k-fold set to 20-fold, and 'scoring' parameter set to 'roc_auc'. This split the data into 20 260 groups, in which 19 groups were model-fitted and the remaining group was tested, which resulted in 20 'roc auc' scores. The average of these scores was used to obtain the prediction 261 262 performance of each model. The model with the highest 'roc auc' average score was chosen

263 (either LR, RF or XGB). Ensembled models were constructed by combining probability scores 264 of nine single-feature base models (TM, GWM, CNA, FLEN, SHORT, LONG, TOTAL, 265 RATIO, EM) with different combination using LR, resulting in one probability score for every 266 sample. An extensive search was performed to evaluate the performance of all possible combinations (n = 511) and the combination with highest AUC was selected as the final model. 267 The model cut-off was set at the threshold specificity of >95%. This combination model 268 performance was evaluated on an independent validation dataset to examine the model 269 classification power. 270

In addition the stacking ensemble, another combinatory strategy was examined. Instead of combining nine base models, we generated a single dataframe consisting of raw data of all nine features. The model hyperparameters tuning and features selecting were followed the same strategy as described above. After choosing the best algorithm, the model performance was also evaluated using the same external validation dataset.

276 **Construction of models for TOO**

277 Strategy 1: Random Forest (RF) model

A single data frame of nine features in discovery cohort was used to train the Random Forest (RF) to classify 5 cancer types. By using the "GridSearchCV" function in the scikit-learn (v.1.0.2), model hyperparameters with the best performance were chosen with 'CV' parameter (cross-validation) set to 3 and "class_weight" parameter set to "balanced". The best hyperparameters were found by function 'best_params_'. Then, the model was validated using kfold cross validation approach on the training cohort with k-fold set to 10-fold and its performance was evaluated on the validation cohort.

285 Strategy 2: Deep neural network (DNN) model

Backpropagation trained the H_2O deep neural network (DNN) (multi-layer feedforward artificial neural network) (H_2O package, version 3.36.1.2) with stochastic gradient descent. The random grid search was selected as previously described (20).

289 Strategy 3: Graph Convolutional Neural Network (GCNN) model

The model training utilized an input graph formed from a discovery dataset and a validation 290 dataset as transudative setting (13) comprising patients diagnosed with five types of cancer: 291 292 breast, colorectal (CRC), gastric, liver, and lung. The discovery dataset contains a set of samplelabel pairs $\mathcal{J} = \{(X_i, Y_i) | i = 1, ..., N\}$ where X_i represents the *i*th sample and Y_i represents *i*th 293 label, and N is the number of sample-label pairs. For each X_i in the discovery dataset, a node's 294 feature vector $f = \{F_0, ..., F_d\} \in \mathbb{R}^d$ is constructed by combining groups of features, where F_i is 295 296 the *i*th feature, d is the number of features. The same procedure was applied for the independent validation dataset. To construct an interaction graph between cancer nodes, we employed the k-297 nearest neighbors' algorithm. An interaction graph defined as G = (V, E) where $V = \{X_i | i = i\}$ 298 1, ..., N} is a node set formed by the discovery samples, and $E = \{e_{ij}\}$ is an edge set, where e_{ij} 299 denotes an edge. Given N nodes in the node set, i.e. |V| = N, a graph topology $A \in \mathbb{R}^{N \times N}$ is 300 301 defined by:

$$A_{ij} = \begin{cases} 1, e_{ij} \in E \text{ and } d_{ij} < \delta \\ 0, otherwise \end{cases}$$

where d_{ij} is the Euclidean distance of node *i* and *j*, and δ is set to 0.8.

In accordance with (22), a Graph Convolutional Neural Network (GCNN) was constructed for the purpose of tissue of origin classification. The network comprised three message-passing

305 layers, each with a hidden size of 44 and a head number of 4. Tissue of origin classification was 306 approached as a node classification problem, wherein the model assigned each node to one of five cancer types: breast, colorectal, gastric, liver or lung cancer. Focal loss was employed for 307 308 multi-class classification optimization and the Adam optimizer was utilized for gradient-based optimization. A 10-fold cross-validation approach was implemented on the discovery dataset; 309 nine groups were used for model training and one group for evaluation. The optimal model was 310 selected based on its ability to achieve the highest accuracy on the validation set during 10-fold 311 cross-validation. This model was subsequently applied to an independent validation dataset 312 313 consisting of 239 cancer patients across five cancer types to obtain the performance of tissue of origin classification. 314

Given the predictions of trained model and the graph topology, we estimated the feature importance score by the GNN Explainer [4]. The feature was considered important if it satisfied:

 $F_i > \delta_f$

where F_i is the important score of *i*th feature estimated by the GNN Explainer, δ_f is the chosen cut-off and was set to 0.9.

319 Statistical analysis

This study used either the Wilcoxon Rank Sum test or t-test to find statistically significant differences between cancer and control. The Kolmogorov-Smirnov test was used to decide whether two cohorts have the same statistical distribution. The Benjamini-Hochberg correction was used to correct p-value for multiple comparisons (with a corrected p-value cutoff $\alpha \le 0.05$). DeLong's test was used to compare the differences between AUCs. All statistical analyses were

- performed using R (4.1.0) packages, including ggplot2, pROC, and caret. 95% confident interval
- 326 (95% CI) was presented in a bracket next to a value accordingly.
- 327 **Results**

328 Clinical characteristics of cancer and healthy participants.

329 This study recruited 738 patients with five common cancer types, including breast cancer 330 (n=223), CRC (n=159), gastric cancer (n=98), liver cancer (n=122), lung cancer (n=136) and 1,550 healthy participants (Table S1). Cancer patients were diagnosed by either imaging and/or 331 histology analysis, depending on cancer type. All cancer patients were treatment-naïve at the 332 333 time of blood collection. Healthy participants had no history of cancer at the time of sample 334 collection and remained cancer-free at the 6- and 12-month follow-ups. Cancer patients and 335 healthy participants were randomly assigned to the discovery and validation cohorts (Table 1 and 336 Table S2). The discovery cohort was used to profile multiple cancer- and tissue-specific 337 signatures and to construct machnine learning algorithm while the validation cohort was used 338 solely to external evaluation of the performance of machine learning models.

The discovery cohort comprised of 499 cancer patients (156 breast, 106 CRC, 67 gastric, 77 liver and 93 lung, Table S1) and 1,076 healthy participants. The cancer group had a median age of 58 (range 25 to 97, Table 1) and consisted of 279 females and 220 males. The discovery healthy group consisted of 599 females and 477 males, with a median age of 47 (range 18 to 84, Table 1). In the discovery cohort, gender ratios were similar between cancer and healthy control groups, whereas cancer patients were older than controls (p< 0.0001, Mann-Whitney test, Table 1). Of the cancer patients, 10.4% were at stage I, 33.9% were at stage II, and 30.1% were at non-

metastatic stage IIIA. Staging information was not available for 25.7% of cancer patients, who
were confirmed by specialized clinicians to have non-metastatic tumors (Table 1).

348 The validation cohort consisted of 239 cancer patients (67 breast, 53 CRC, 31 gastric, 45 liver 349 and 43 lung, Table S1) and 474 healthy participants (Table 1). Consistent with the discovery 350 cohort, the gender distribution was comparable between the cancer and healthy control groups, 351 and the cancer group was older than the control group, with a median age of 59 and 48 years old, 352 respectively (p<0.0001, Mann-Whitney test, Table 1). The percentage of cancer patients with 353 each stage was similar to that of the discovery cohort, with 9.6% at stage I, 28.9% at stage II and 354 32.2% at stage IIIA. Staging information was unavailable for 29.3% of non-metastatic cancer 355 patients (Table 1).

356 The multimodal SPOT-MAS assay for multi-cancer and tissue of origin detection

357 In our recent study of SPOT-MAS, we have demonstrated that the integration of ctDNA methylation and fragmentomic features can significantly improve the early detection of 358 359 colorectal cancer (20). Here, we expanded the breadth of ctDNA analyses by adding two sets of 360 features including DNA copy number and end motif into SPOT-MAS to maximize cancer detection rate and identify TOO. Briefly, a novel and cost-effective workflow of SPOT-MAS 361 362 was developed involving three main steps (Figure 1). In step 1, cfDNA was isolated from 363 peripheral blood and subjected to bisulfite conversion and adapter ligation to create a single 364 whole-genome bisulfite library of cfDNA. From this library, in step 2, a hybridization reaction was performed to collect the target capture fraction (450 cancer specific regions), then the whole-365 genome fraction was retrieved by collecting the 'flow-through' and hybridizing with probes 366 367 specific for adapter sequences of DNA library. Both the target capture fraction and wholegenome fraction were sequenced to the depth of \sim 52X and 0.55X, respectively (Table S3). Data 368

pre-processing was performed to generate five different sets of cfDNA features, including methylation changes at target regions (TM), genome-wide methylation (GWM), fragment length patterns (Flen), copy number aberrations (CNA) and end motif (EM). In step 3, these features were used as inputs for a two-stage model to obtain prediction outcomes. Stage 1 of our model comprised of a stacked ensemble machine learning model for binary classification of cancer versus healthy. Then the samples predicted as cancer were passed to stage 2 where graph convolution neural network (GCNN) was adopted to predict TOO (Figure 1).

Identification of differentially methylated regions (DMRs) in cancer patients from target capture fraction

DNA methylation is an important epigenetic signature responsible for major changes in 378 regulating expression of cancer associated genes by impacting the binding of transcription 379 380 factors to regulatory sites and the structure of chromatin (26, 27). Of the 450 target regions associated with cancer that were selected from public data (13, 22), 402 regions were identified 381 382 as differentially methylated regions (DMRs) in cancer patients when compared to healthy participants from the discovery cohort (Wilcoxon rank-sum test, p-values < 0.05, Figure 2A and 383 Table S4). Of those, 339 (84.3%) regions were identified as hypermethylated (logFC > 0), and 384 385 63 (15.7%) regions as hypomethylated in cancer samples (logFC < 0, Figure 2A). We next 386 examined the genomic location of the 402 DMRs and found 100, 108, 107 and 87 DMRs that were mapped to promoter, exon, intron and intergenic regions, respectively (Figure 2B). To 387 388 understand the relationship between the differences in methylation regions and biological 389 pathways, we performed pathway enrichment analysis using g:Profiler on hypermethylated 390 DMRs. We detected 36 enriched pathways, including 14 from Kyoto Encyclopedia of Genes and 391 Genomes (KEGG) and 22 from WikiPathway (WP) (Figure 2C and Table S5). These significant

pathways were known to regulate tumorigenesis of breast, gastric, hepatocellular, and colorectal
cancer. Therefore, the methylation changes in the targeted regions, particularly the
hypermethylated DMRs, mostly occur early in tumorigenesis and are crucial for distinguishing
early-stage cancer patients from healthy individuals.

Genome-wide methylation changes in cfDNA of cancer patients

397 In addition to site-specific hypermethylation, hypomethylation is a significant genome-wide change that has been identified in many types of cancers (24, 28, 29). To investigate the 398 399 methylation changes at genome-wide level, bisulfite sequencing reads from the whole-genome 400 fraction were mapped to the human genome, split into bins of 1Mb (2,734 bins across the genome), and the reads from each bin were used to calculate methylation ratio. As expected, we 401 402 observed a left-ward shift in the distribution of methylation ratio in cancer samples compared to 403 healthy controls, indicating global hypomethylation in the cancer genome (p < 0.0001, twosample Kolmogorov-Smirnov test, Figure 3A). Of these bins, we identified 1,715 (62.7%) bins 404 405 as significantly hypomethylated in cancer, located across 22 autosomes of the genome (Figure 3B, Wilcoxon rank sum test with Benjamini-Hochberg adjusting p-value <0.05). In contrast, 406 there were only 10 bins identified as hypermethylated and mapped to chromosome 1, 2, 3, 5, 6, 7 407 408 and 12 in the cancer genome (Figure 3B). Therefore, our data confirmed the widespread hypomethylation across the genome and this would potentially serve to distinguish cancer 409 patients from healthy controls. 410

411 Increase DNA copy number aberrations (CNAs) in cfDNA of cancer patients

Somatic copy number aberrations (CNAs) in the cancer genome are associated with the initiationand progression of numerous cancers by altering transcriptional levels of both oncogenes and

414 tumor suppressor genes (30). Recent studies have shown that CNAs detection could identify and 415 quantify the fraction of ctDNA in plasma cfDNA (31-33). To examine CNAs at genome-wide scale, we used 1Mb bin to determine the percentage of bins that showed significant copy number 416 417 gains or losses between cancer and control group. We identified 729 bins (27.1%) with a significant gain and 976 bins (36.3%) with a significant loss in copy number across 22 418 419 chromosomes of the cancer genome (Benjamini-Hochberg adjusting p-value <0.05, Wilcoxon 420 rank sum test, Figure 4A). We noted that chromosome 8 had the highest proportion of bins with CNA gains, while chromosome 22 showed the highest proportion of bins with CNA losses 421 422 (Figure 4B).

423 It is thought that the abnormal hypomethylation at genome-wide level is linked with somatic copy number aberration (CNA), resulting in genome instability, which is an important 424 425 tumorigenic event (34-36). Indeed, our data showed a significant increase in levels of CNA in 426 hypomethylated bins compared to bins with unchanged methylation (p=0.024, Figure S1A). Consistently, bins with CNA gains showed significant decreases in methylation as compared to 427 428 those with CNA losses or unchanged CNA (p<0.01, Figure S1B). In summary, SPOT-MAS 429 enables comprehensive profiling of both global differences in methylation and somatic CNA as 430 individual feature types, as well as exploring their functional links during cancer initiation and development, rendering them ideal biomarkers for cancer detection. 431

432 Fragment length analysis captured patterns of ctDNA in plasma

Several studies have shown that the fragmentation pattern of cfDNA is a non-random event mediated by apoptotic-dependent caspases and ctDNA fragments tend to be shorter than noncancer cfDNA (14, 23, 37-39). One novel technical aspect of SPOT-MAS is the use of bisulfite sequencing data not only for methylation but also for fragment length analysis. Certain studies

437 showed evidence of DNA degradation followed bisulfite treatment, possibly due to high 438 temperature and low pH conditions of the bisulfite conversion procedure, while other showed that bisulfite sequencing affects large genomic DNA but not small size cfDNA (40-43). 439 440 Therefore, to demonstrate the use of bisulfite treated cfDNA for fragment length analysis, we randomly selected 3 healthy controls and 9 cancer samples to perform pair-wise comparison 441 between bisulfite and non-bisulfite sequencing results. We observed a strong correlation between 442 fragment length profile of non-bisulfite and bisulfite sequencing (Pearson correlation, $R^2 > 0.9$, 443 p<0.0001, Figure S2A) for all 12 tested samples, indicating the feasibility of using bisulfite 444 445 sequencing data for cfDNA fragment length analysis. Indeed, the fragment size distributions of bisulfite-treated cfDNA in both cancer patients and control subjects showed a peak at 167 bp 446 (Figure 5A), corresponding to the length of DNA wrapped around histone ($\sim \Box 147$ bp) plus 447 linker regions ($\sim \Box 2x10$ bp), which was in good agreement with previous studies using non-448 449 bisulfite cfDNA (14, 25). Importantly, our results showed that cfDNA of cancer patients was 450 more fragmented than that of healthy participants, with a higher frequency of fragments ≤ 150 bp 451 and a lower frequency of fragment > 150 bp (Figure 5A).

To examine whether the fragment length variation in cancer-derived cfDNA and non-cancer cfDNA could be position-dependent (14), we calculated the ratios of short (\leq 150bp) to long fragments (> 150 bp) across the genome in cancer patients and healthy controls. The mean ratio of short to long fragments in cancer patients was 0.29 (range 0.28 to 0.42), which was higher than the mean ratio of 0.27 (range 0.26 to 0.39) for healthy controls (Figure 5B). The changes of mean ratio were across 22 autosomes of the genome. Our results indicate that the SPOT-MAS technology can effectively capture differences in fragmentation patterns between cancer and

459 healthy participants across the entire genome, making them potential biomarkers for the460 detection of circulating tumor DNA in plasma.

461 Profile of 4-mer end motifs reflecting differences between cancer and healthy cfDNA

Associated with differences in fragment length is the differences in the DNA motifs at the end of 462 463 each fragment as the consequences of differential cleavage between DNA in cancer cells and 464 normal cells during apoptosis (25, 44). Here, we calculated the frequencies of 256 4-mer end motifs (EMs) of cfDNA fragments and compared them between cancer patients and healthy 465 participants. Consistent with the fragment length features, we also confirmed the correlation of 466 467 EM frequency between bisulfite and non-bisulfite sequencing results of 12 randomly selected samples, suggesting that EM profiles were reserved in bisulfite treated cfDNA (Figure S2B). Of 468 the 256 4-mer EMs, we detected 78 motifs with increased frequencies and 106 motifs with 469 470 decreased frequencies between cancer and healthy controls (Figure 6A and Table S6).

471 Interestingly, EMs beginning with cytosine (C) exhibited the highest number of EMs with 472 significant changes of frequency in cancer samples (Figure 6A). Figure 6B shows the top ten 473 EMs exhibiting significant differences. Specifically, the frequencies of five motifs (CAAA, TAGA, CAGA, CAAG, and CAAT) were found to be significantly increased, while the 474 475 frequencies of another five motifs (CGCT, CGCC, CGCA, GCCT, and CGTT) were significantly decreased in cancer patients (Figure 6B). Therefore, the differences in end motif 476 frequency identified by SPOT-MAS between cancer patients and healthy participants may serve 477 as a promising target for the identification of ctDNA. 478

479 SPOT-MAS assay combining different features of cfDNA to enhance the accuracy of
 480 cancer detection

481 In order to increase the sensitivity of early cancer detection while avoiding the high cost of deep 482 sequencing, a screening test should survey a wide range of ctDNA signatures (16). Therefore, we utilized multiple ctDNA signatures to construct classification models for distinguishing cancer 483 484 patients from healthy individuals. To expand the feature space, we generated four additional features based on fragment length, including short, long, total fragment count, and short-to-long 485 ratio, resulting in nine input feature groups (Figure 7A). For each feature group, we tested three 486 different algorithms, including random forest (RF), logistic regression (LR), or extreme gradient 487 boosting (XGB), to tune hyperparameters and select the optimal algorithms (Figure 7A). To 488 489 evaluate the performance of these single-feature models, we performed 20-fold cross-validation 490 on the discovery dataset and calculated "Area Under the Curve" (AUC) of the "Receiver Operating Characteristic" (ROC) curve. Among the nine features, EM-based model showed the 491 highest AUC of 0.90 (95% CI: 0.89-0.92, Figure 7B) while the SHORT-based model had the 492 lowest AUC of 0.71 (95% CI: 0.69-0.74, Figure 7B). 493

To assess whether combining features could improve classification, we used two strategies to 494 495 construct multi-feature models. In the first strategy, all nine feature groups were concatenated 496 into a single data frame before being fed into the RF, LR, or XGB algorithms. Of the three algorithms, the XGB model exhibited the best performance with an AUC of 0.88 (95% CI: 0.87-497 0.90, Figure 7B). However, this AUC is still lower than that of the EM-based model (0.88 versus 498 0.90, Figure 7B). In the second strategy, we constructed an ensemble stacking model using 499 500 logistic regression to combine the prediction results of the single-feature models. We conducted 501 an exhaustive search approach to evaluate the performance of 511 possible combinations. The 502 stacking ensemble model based on combining eight features, including TM, GW, CNA, FLEN, 503 LONG, TOTAL, RATIO and EM, exhibited the best performance and outperformed the single-

feature models (Table S7), with an AUC of 0.93 (95% CI: 0.92-0.95, Figure 7B and Figure S3).
In the independent validation cohort, we obtained similar results, where the ensemble model also
outperformed single-feature models, with an AUC of 0.95 (95% CI: 0.93-0.96, Figure 7C).

507 In order to ensure cost-effectiveness and minimize psychological impact of cancer screening tests in a large population, high specificity is a crucial requirement. Accordingly, we established 508 509 the cutoff value for each constructed model based on a minimum specificity threshold of 95%. 510 Of the nine single-feature models, EM and GWM models exhibited the highest sensitivities, at 511 59.5% and 60.9%, respectively. The stacking ensemble model achieved a sensitivity of 73.8% 512 and a specificity of 95.1% with a cutoff value of 0.546 in the discovery cohort (Figure 7D), and a 513 mean sensitivity of 72.4% and a specificity of 97.0% in the validation cohort (Figure 7E). 514 Stratification of samples by cancer types revealed that the ensemble model performed most 515 accurately in predicting liver cancer (89.6% sensitivity), followed by CRC (82.1% sensitivity m), 516 lung cancer (78.5% sensitivity) and gastric cancer (71.6% sensitivity) (Figure 7F, Table S8). 517 Breast cancer had the lowest detection rate of 58.3% (91/156 patients). Importantly, the 518 performance of our ensemble model remained consistent in the validation cohort, with liver cancer again showing the highest sensitivity (91.1%), followed by lung cancer (83.7%), CRC 519 520 (83.0%), gastric cancer (61.3%), and breast cancer (49.3%) (Figure 7G, Table S8).

521 Influence of clinical features on model prediction

522 Upon stratifying our dataset by gender, we found that there was no significant difference in the 523 prediction of healthy status between males and females (Figure S4A and S4C). However, in the 524 case of cancer prediction, our model demonstrated higher accuracy in males than females in both 525 the discovery and validation cohorts (Figure S4A and S4C). Notably, when breast cancer 526 samples were removed from our analysis, there was no difference in the detection rates between

male and female patients (Figure S4B and S4D), suggesting that the observed gender bias may be attributed to the high proportion of breast cancer patients (all females) in our cohort, who exhibited the lowest detection rate among the five cancer groups.

530 We next evaluated the potential confounding effect of age on our prediction model by examining the correlation between the model prediction scores and the participants' ages. The results 531 532 revealed no significant correlation, suggesting that age differences are unlikely to affect the 533 accuracy of our model (Figure S4E and S4F). With regards to cancer burden (ie. tumor size), our model performed better for cancers with higher burden, as reflected by the higher cancer scores 534 535 assigned to these cases (Figure S4G and S4H). Specifically, patients with tumor diameter ≥ 3.5 536 cm were more likely to be detected than those with a diameter < 3.5 cm (Figure S4G and S4H). Similarly, cancer stages also influence the performance of our stacking ensemble model, 537 538 showing increasing detection accuracy as the stages get more advanced. In the discovery cohort, 539 the model's accuracy was highest for stage IIIA cancers, with an AUC of 0.95 (95% CI 0.93-0.97), and lowest for stage I cancer, with an AUC of 0.90 (95% CI 0.86-0.95) (Figure S4I and 540 541 S4J). Consistently, our model performance was lower with an AUC of 0.94 (95% CI 0.89-0.98) 542 and 0.93 (95% CI 0.90-0.96) for stage I and II cancer, respectively, increasing to 0.98 (95% CI 543 0.97-0.99) for stage IIIA in the validation cohort (Figure S4K and S4L). These results demonstrated that our ensemble model can detect cancers at all stages found in our cohorts, 544 545 despite a slightly lower performance in early stages (stage I and II) compared to non-mestatatic 546 stage (IIIA).

547 SPOT-MAS enables prediction of cancer types

The ability to predict the tissue origin of ctDNA is critical for early cancer detection as this can guide subsequent diagnostic tests and treatment. Previous studies have attempted to use either

550 fragment length or methylation landscapes to achieve this goal (5, 14, 45). In this study, we 551 demonstrated the ability of SPOT-MAS to identify the TOO using low-depth bisulfite 552 sequencing to generate multiple sets of cfDNA features. We first concatenated the nine sets of 553 cfDNA features into a single data frame and focused our analysis on 499 cancer patients with five cancer types in the discovery cohort. We then constructed a Random Forest (RF) and two 554 555 neural network models (convolutional neural network and graph convolutional neural network) 556 to predict the TOO and used 10-fold cross-validation to estimate and compare the performance 557 of these models (Figure 8A and Figure S5A). The Graph Convolutional Neural Network 558 (GCNN) was chosen due to its superior performance and stability (Figure S5B and S5C and Table S9). 559

We then used the GNNExplainer tool to measure the importance of different cfDNA features. 560 561 Our results showed that breast cancer had the highest number of features with an important score 562 >0.9 (497 features), while lung cancer had the lowest number of important features (126) features) (Figure 8B). Colorectal, gastric, and liver cancers had 363, 309, and 204 important 563 564 features, respectively (Figure 8B and Table S10). Genome-wide methylation and copy number 565 aberration were the most important features for differentiating breast, colorectal, CRC, gastric 566 and liver cancer from other cancer types, while the end motif had the lowest contribution to distinguish cancer types (Figure 8C). Visualization of the 3D GCNN showed that this set of 567 discriminative features could segregate the five different cancer types (Figure 8D), highlighting 568 569 the benefits of a multimodal approach for predicting TOO.

570 The median accuracy for TOO identification among the five cancer types by the GCNN-based 571 multi-feature model was 0.73 (range 0.54 to 0.87) in the discovery cohort (Figure 8E). The 572 accuracy in the discovery cohort was highest for breast (0.87) and liver cancer (0.82) and lowest

573 for gastric cancer (0.54). In the validation cohort, we obtained a slightly lower accuracy with a 574 median of 0.70 (range 0.55 to 0.78). The accuracies for individual cancer types were 0.78 for 575 breast, 0.76 for liver, 0.66 for colorectal, 0.63 for lung and 0.55 for gastric cancer (Figure 8F). 576 Among the 5 cancer types, breast cancer showed the highest TOO accuracy, possibly due to the highest number of important features detected by the model. In contrast, CRC and gastric cancer 577 578 exhibited the lowest TOO accuracy with high misprediction rates between these two cancer types 579 (0.11 and 0.19 for CRC versus gastric and gastric versus CRC, respectively). Together, our study highlights the benefits of integrating multimodal analysis with the GCNN model to capture the 580 581 broad landscape of tissue-specific markers in different cancer types.

582 Discussion

In an era marked by a global rise in cancer-related morbidity and mortality, the development of 583 liquid biopsy screening tests that can detect and localize cancer at an early stage holds 584 tremendous potential to revolutionize cancer diagnosis and therapy. Despite this, challenges in 585 586 test performance and cost must still be overcome, due mostly to the limited abundance of ctDNA 587 and its inherent variability. To address these, published liquid biopsy assays to date demanded a very high-depth sequencing (15), or a combination of protein and genetic biomarkers (19), 588 589 resulting in an elevated price of test. In the current study, we present the SPOT-MAS assay as a 590 single workflow with comparable performance to current tests while requiring a much lower sequencing depth (Table S11). SPOT-MAS achieved a sensitivity of 72.4 % at a specificity of 591 592 97.0 % for detecting five common cancer types using shallow depth sequencing. Furthermore, it can predict the tissue of origin with an accuracy of 70%. 593

594 The SPOT-MAS assay allows comprehensive investigation of multiple biomarkers in cfDNA, 595 including targeted methylation (TM), genome-wide methylation (GWM), copy number

596 aberration (CNA), end motif (EM) and fragment length profiles (Flen). In TM analysis, out of 597 450 TM regions chosen from previous publications (13, 22), we identified 402 regions as significant differentially methylated regions (DMRs) in cancer patients (Figure 2A). These 598 599 DMRs were enriched for regulatory regions of well-known cancer-related gene families such as PAX family genes, TBX family genes, FOX family genes and HOX family genes, and some 600 have previously been reported as biomarkers for noninvasive cancer diagnosis, such as SEPT9 601 602 and SHOX2 (46, 47). In addition to the targeted hypermethylation regions, our study also showed 603 widespread hypomethylation patterns across 22 autosomes of cancer patients (Figure 3), a 604 hallmark of cancer (48). Importantly, we demonstrated that the same bisulfite sequencing data could be used to identify somatic CNA (Figure 4), cancer-associated fragment length (Figure 5) 605 and end motifs (Figure 6), highlighting the advantage of SPOT-MAS in capturing the broad 606 607 landscape of ctDNA signatures without high cost deep sequencing. For cancer-associated fragment length, we pre-processed this data into five different feature tables to better reflect the 608 information embedded within the data. Overall, nine feature tables are available for model 609 610 construction.

The involvement and orthogonal links of the above features in the transcriptional regulation of 611 612 cancer-associated genes during carcinogenesis prompted us to examine whether the combination 613 of multiple cancer-specific signatures in cfDNA could improve the efficiency of cancer detection (49, 50). We first determined the performance of models constructed using individual type of 614 615 cfDNA features. Next, by performing exhaustive searches for all possible combinations of 616 single-feature models, we identified that the stacking ensemble of seven features could achieve the AUC of 0.95 (95% CI: 0.93-0.96, Figure 8C and Figure S3), which is superior to all single-617 618 feature models. Among the five cancer types, breast cancer showed the lowest detection rate of

619 58.3% and 49.3% in the discovery and validation cohort, respectively. Variations in detection 620 rates among different cancer types have been previously reported (5, 19, 45). Consistently, it has 621 been reported that the detection of breast cancer, particularly in early stages, is challenging due 622 to the low levels of ctDNA shedding and heterogeneity of molecular subtypes of breast tumors (5). In contrast, we obtained the highest detection rate for liver cancer patients with the 623 sensitivity of 89.6% and 91.1% in the discovery and validation cohort, respectively. Our finding 624 is in good agreement with the literature showing that liver tumors shed high amounts of ctDNA 625 (51). This result demonstrated the advantage of a multimodal approach to enhance ctDNA 626 627 detection in plasma. We also conducted a survey of liquid biopsy assays to put our SPOT-MAS into the context of current state-of-the art in the field. Table S11 showed that SPOT-MAS is 628 using the lowest sequencing depth approach (with a depth coverage of $\sim 0.55X$) and making up 629 for this by integrating the greatest number of cfDNA features to achieve comparable 630 performance to other assays. 631

For TOO identification, our results showed that the graph convolutional neural network (GCNN) 632 633 performed the best among the models tested (Figure S5 and Figure 8). GCNN has the ability to 634 explore the similarity and mutual representation among samples, therefore achieving great 635 success in multi-class classification tasks (52, 53). Unlike the reference-based deconvolution approaches (54, 55), our GCNN approach is independent of a reference methylation atlas, which 636 was developed from tissue or cell type specific methylation markers and thus may introduce bias 637 638 due to discordance between the methylomes of tissue gDNA and plasma cfDNA (16, 56). Although the methylation changes were reported as most predictive for TOO in previous studies 639 (54, 55), our results showed the contribution of each of the 9 features for TOO identification 640 641 (Figure 8C). In addition to GWM, fragment ratio (RATIO) and CNA are the major contributors

642 to the discrimination of different tissue types. This finding provided additional evidence that the 643 multimodal approach capturing the breadth of tissue-specific signatures could improve the accuracy of TOO identification (5). Our GCNN model achieved an accuracy of 0.70 for TOO 644 645 prediction in validation cohort. This was comparable to the performance of CancerLocator, which was based a probabilistic distribution model of tissue specific methylation markers (57). 646 647 Recently, Liu et al. (5) developed a methylation atlas based method, which achieved a higher accuracy of 93% for locating 50 types of cancer. However, this approach is based on deep 648 genome-wide sequencing with high depth coverage of 30X (Table S11), thus might not be a cost 649 650 effective approach for cancer screening in large populations, especially in low-income countries.

There are several limitations in our study. First, despite using a large dataset of 738 cancer 651 samples, there was an unequal distribution of samples among cancer types, with breast cancer 652 653 accounting for 30.2% (223/738, Table S2) of the total samples and gastric cancer having a much 654 smaller representation (13.3%, Table S2). As a result, our models may have been influenced by 655 this imbalance, potentially introducing bias in the training and evaluation process. Therefore, 656 future studies should consider incorporating more samples to better estimate the overall 657 performance of the SPOT-MAS test. Second, tumor staging information was not available for 658 26.8% of cancer patients (198/738) in our study. This is due to the patients' decision to select 659 different hospitals for diagnostics and treatment, leading to missing histopathological information at the hospitals where they were originally recruited. However, all cancer patients 660 661 recruited in this study were confirmed to have non-metastatic tumors. Third, the cancer patients 662 in both the discovery and validation cohort were older than the healthy participants. Age differences could be a confounding variable of methylation and could affect the model 663 664 performance (58, 59). However, we observed no significant association between the participants'

665 age and model prediction scores (Figure S4). Fourth, the ability of SPOT-MAS to differentiate 666 cancer patients from those with benign lesions has not been examined in this study. Fifth, this 667 study only focused on the top 5 common cancer types, thus the current version of SPOT-MAS 668 might misidentify cancer patients of other types, resulting in lower sensitivity to real world application. Lastly, this was a retrospective cohort study and may be biased by the nature of this 669 study design. In an interim 6-month report of a prospective study named K-DETEK, we were 670 671 encouraged by the preliminary data demonstrated the ability of SPOT-MAS to detect cancer patients who exhibited no symptoms at the time of testing (60). Despite these promising results, 672 673 the performance of SPOT-MAS as an early cancer screening test remains to be fully validated in 674 a large, multi-center prospective study with 1 to 2 years of follow up.

675 Conclusions

In conclusion, we have developed the SPOT-MAS assay to comprehensively profile methylomic, fragmentomic, copy number aberrations, and motif end signatures of plasma cfDNA. Our largescale case-control study demonstrated that SPOT-MAS, with its unique combination of multimodal analysis of cfDNA signatures and innovative machine-learning algorithms, can successfully detect and localize multiple types of cancer at a low-cost sequencing. These findings provided important supporting evidence for the incorporation of SPOT-MAS into clinical settings as a complementary cancer screening method for at-risk populations.

683

684 **References**

1.	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global							
Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36								
Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209-49.								
2.	Pham T, Bui L, Kim G, Hoang D, Tran T, Hoang M. Cancers in Vietnam-Burden and							
Control Efforts: A Narrative Scoping Review. Cancer Control. 2019;26(1):1073274819863802.								
3.	Hawkes N. Cancer survival data emphasise importance of early diagnosis. BMJ.							
2019;364:1408.								
4.	Kakushadze Z, Raghubanshi R, Yu W. Estimating Cost Savings from Early Cancer							
Diagnosis. Data [Internet]. 2017; 2(3).								
5.	Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV. Sensitive and specific multi-							
cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol								
2020;31(6):745-59.								
6.	Li J, Han X, Yu X, Xu Z, Yang G, Liu B, et al. Clinical applications of liquid biopsy as							
prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and								
circulating tumor DNA. J Exp Clin Cancer Res. 2018;37(1):213.								
7.	Nguyen HT, Luong BA, Tran DH, Nguyen TH, Ngo QD, Le LGH, et al. Ultra-Deep							
Sequencing of Plasma-Circulating DNA for the Detection of Tumor- Derived Mutations in								
Patient	s with Nonmetastatic Colorectal Cancer. Cancer Invest. 2022;40(4):354-65.							
8.	Gao Q, Zeng Q, Wang Z, Li C, Xu Y, Cui P, et al. Circulating cell-free DNA for cancer							
early d	etection. The Innovation. 2022;3(4):100259.							
	 Cancer Cancer Control Control 2019;3 4. Diagnol Cancer 2020;3 G. prognol circula 7. Sequer Patient 8. early d 							

705 9. Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, et al. 706 ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: 707 a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022;33(8):750-68. 708 10. Nguyen HT, Tran DH, Ngo QD, Pham HT, Tran TT, Tran VU, et al. Evaluation of a Liquid Biopsy Protocol using Ultra-Deep Massive Parallel Sequencing for Detecting and 709 710 Quantifying Circulation Tumor DNA in Colorectal Cancer Patients. Cancer Invest. 711 2020;38(2):85-93. 712 Constantin N, Sina AA, Korbie D, Trau M. Opportunities for Early Cancer Detection: 11. 713 The Rise of ctDNA Methylation-Based Pan-Cancer Screening Technologies. Epigenomes. 714 2022;6(1). Phan TH, Chi Nguyen VT, Thi Pham TT, Nguyen VC, Ho TD, Quynh Pham TM, et al. 715 12. Circulating DNA methylation profile improves the accuracy of serum biomarkers for the 716 717 detection of nonmetastatic hepatocellular carcinoma. Future Oncol. 2022;18(39):4399-413. Chen X, Gole J, Gore A, He Q, Lu M, Min J, et al. Non-invasive early detection of 718 13. 719 cancer four years before conventional diagnosis using a blood test. Nature Communications. 2020;11(1):3475. 720 Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, et al. Genome-wide cell-721 14. 722 free DNA fragmentation in patients with cancer. Nature. 2019;570(7761):385-9.

Jamshidi A, Liu MC, Klein EA, Venn O, Hubbell E, Beausang JF, et al. Evaluation of
cell-free DNA approaches for multi-cancer early detection. Cancer Cell. 2022;40(12):153749.e12.

Moser T, Kühberger S, Lazzeri I, Vlachos G, Heitzer E. Bridging biological cfDNA
features and machine learning approaches. Trends Genet. 2023;39(4):285-307.

728	17. Im YR, Tsui DWY, Diaz LA, Jr., Wan JCM. Next-Generation Liquid Biopsies:
729	Embracing Data Science in Oncology. Trends Cancer. 2021;7(4):283-92.
730	18. Zhou Q, Kang G, Jiang P, Qiao R, Lam WKJ, Yu SCY, et al. Epigenetic analysis of cell-
731	free DNA by fragmentomic profiling. Proceedings of the National Academy of Sciences.
732	2022;119(44):e2209852119.
733	19. Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and
734	localization of surgically resectable cancers with a multi-analyte blood test. Science.
735	2018;359(6378):926-30.
736	20. Nguyen HT, Khoa Huynh LA, Nguyen TV, Tran DH, Thu Tran TT, Khang Le ND, et al.
737	Multimodal analysis of ctDNA methylation and fragmentomic profiles enhances detection of
738	nonmetastatic colorectal cancer. Future Oncol. 2022;18(35):3895-912.
739	21. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the
740	AJCC Cancer Staging Manual and the Future of TNM. Annals of Surgical Oncology.
741	2010;17(6):1471-4.
742	22. Nguyen H-N, Cao N-PT, Van Nguyen T-C, Le KND, Nguyen DT, Nguyen Q-TT, et al.
743	Liquid biopsy uncovers distinct patterns of DNA methylation and copy number changes in
744	NSCLC patients with different EGFR-TKI resistant mutations. Scientific Reports.
745	2021;11(1):16436.
746	23. Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, et al.
747	Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med.
748	2018;10(466).
749	24. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene.

750 2002;21(35):5400-13.

Jiang P, Sun K, Peng W, Cheng SH, Ni M, Yeung PC, et al. Plasma DNA End-Motif
Profiling as a Fragmentomic Marker in Cancer, Pregnancy, and Transplantation. Cancer
Discovery. 2020;10(5):664-73.

Yin Y, Morgunova E, Jolma A, Kaasinen E, Sahu B, Khund-Sayeed S, et al. Impact of
cytosine methylation on DNA binding specificities of human transcription factors. Science.
2017;356(6337).

757 27. Buitrago D, Labrador M, Arcon JP, Lema R, Flores O, Esteve-Codina A, et al. Impact of
758 DNA methylation on 3D genome structure. Nature Communications. 2021;12(1):3243.

28. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol. 2004;22(22):4632-42.

760 29. Hoffmann MJ, Schulz WA. Causes and consequences of DNA hypomethylation in
761 human cancer. Biochem Cell Biol. 2005;83(3):296-321.

- 30. Shao X, Lv N, Liao J, Long J, Xue R, Ai N, et al. Copy number variation is highly
 correlated with differential gene expression: a pan-cancer study. BMC Med Genet.
 2019;20(1):175.
- 31. Baldacchino S, Grech G. Somatic copy number aberrations in metastatic patients: The
 promise of liquid biopsies. Semin Cancer Biol. 2020;60:302-10.
- 767 32. Knuutila S, Aalto Y, Autio K, Björkqvist AM, El-Rifai W, Hemmer S, et al. DNA copy
 768 number losses in human neoplasms. Am J Pathol. 1999;155(3):683-94.
- 769 33. Dereli-Öz A, Versini G, Halazonetis TD. Studies of genomic copy number changes in
- human cancers reveal signatures of DNA replication stress. Mol Oncol. 2011;5(4):308-14.
- 34. Brennan K, Flanagan JM. Is there a link between genome-wide hypomethylation in blood
- and cancer risk? Cancer Prev Res (Phila). 2012;5(12):1345-57.

- 773 35. Zhang W, Klinkebiel D, Barger CJ, Pandey S, Guda C, Miller A, et al. Global DNA
- 774 Hypomethylation in Epithelial Ovarian Cancer: Passive Demethylation and Association with
- 775 Genomic Instability. Cancers (Basel). 2020;12(3).
- 776 36. Chan KCA, Jiang P, Chan CWM, Sun K, Wong J, Hui EP, et al. Noninvasive detection
- of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma
 DNA bisulfite sequencing. Proceedings of the National Academy of Sciences.
- 779 2013;110(47):18761-8.
- 37. Underhill HR, Kitzman JO, Hellwig S, Welker NC, Daza R, Baker DN, et al. Fragment
 Length of Circulating Tumor DNA. PLOS Genetics. 2016;12(7):e1006162.
- 38. Lo YMD, Han DSC, Jiang P, Chiu RWK. Epigenetics, fragmentomics, and topology of
 cell-free DNA in liquid biopsies. Science. 2021;372(6538):eaaw3616.
- Nguyen VC, Nguyen TH, Phan TH, Tran TT, Pham TTT, Ho TD, et al. Fragment length
 profiles of cancer mutations enhance detection of circulating tumor DNA in patients with earlystage hepatocellular carcinoma. BMC Cancer. 2023;23(1):233.
- Raizis AM, Schmitt F, Jost JP. A bisulfite method of 5-methylcytosine mapping that
 minimizes template degradation. Anal Biochem. 1995;226(1):161-6.
- Tanaka K, Okamoto A. Degradation of DNA by bisulfite treatment. Bioorg Med Chem
 Lett. 2007;17(7):1912-5.
- Kint S, De Spiegelaere W, De Kesel J, Vandekerckhove L, Van Criekinge W. Evaluation
 of bisulfite kits for DNA methylation profiling in terms of DNA fragmentation and DNA
 recovery using digital PCR. PLoS One. 2018;13(6):e0199091.
- 43. Ehrich M, Zoll S, Sur S, van den Boom D. A new method for accurate assessment of
 DNA quality after bisulfite treatment. Nucleic Acids Res. 2007;35(5):e29.

- 44. Jin C, Liu X, Zheng W, Su L, Liu Y, Guo X, et al. Characterization of fragment sizes,
- copy number aberrations and 4-mer end motifs in cell-free DNA of hepatocellular carcinoma for
- enhanced liquid biopsy-based cancer detection. Mol Oncol. 2021;15(9):2377-89.
- 45. Klein EA, Richards D, Cohn A, Tummala M, Lapham R, Cosgrove D, et al. Clinical
- validation of a targeted methylation-based multi-cancer early detection test using an independent
- validation set. Ann Oncol. 2021;32(9):1167-77.
- 46. Ilse P, Biesterfeld S, Pomjanski N, Wrobel C, Schramm M. Analysis of
 SHOX2 Methylation as an Aid to Cytology in Lung Cancer Diagnosis.
 Cancer Genomics Proteomics. 2014;11(5):251.
- Warren JD, Xiong W, Bunker AM, Vaughn CP, Furtado LV, Roberts WL, et al. Septin 9
 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med.
 2011;9:133.
- 48. Jones PA, Ohtani H, Chakravarthy A, De Carvalho DD. Epigenetic therapy in immuneoncology. Nat Rev Cancer. 2019;19(3):151-61.
- 49. Ulz P, Perakis S, Zhou Q, Moser T, Belic J, Lazzeri I, et al. Inference of transcription
 factor binding from cell-free DNA enables tumor subtype prediction and early detection. Nat
 Commun. 2019;10(1):4666.
- 50. Ivanov M, Baranova A, Butler T, Spellman P, Mileyko V. Non-random fragmentation
 patterns in circulating cell-free DNA reflect epigenetic regulation. BMC Genomics. 2015;16
 Suppl 13(Suppl 13):S1.
- S1. Caggiano C, Celona B, Garton F, Mefford J, Black BL, Henderson R, et al.
 Comprehensive cell type decomposition of circulating cell-free DNA with CelFiE. Nature
 Communications. 2021;12(1):2717.

- S19 52. Yin C, Cao Y, Sun P, Zhang H, Li Z, Xu Y, et al. Molecular Subtyping of Cancer Based
 on Robust Graph Neural Network and Multi-Omics Data Integration. Front Genet.
 2022;13:884028.
- 822 53. Huang Y, Chung ACS. Disease prediction with edge-variational graph convolutional
 823 networks. Med Image Anal. 2022;77:102375.
- Moss J, Magenheim J, Neiman D, Zemmour H, Loyfer N, Korach A, et al.
 Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in
 health and disease. Nature Communications. 2018;9(1):5068.
- 55. Loyfer N, Magenheim J, Peretz A, Cann G, Bredno J, Klochendler A, et al. A DNA
 methylation atlas of normal human cell types. Nature. 2023;613(7943):355-64.
- 56. Zhou X, Cheng Z, Dong M, Liu Q, Yang W, Liu M, et al. Tumor fractions deciphered
 from circulating cell-free DNA methylation for cancer early diagnosis. Nature Communications.
 2022;13(1):7694.
- Kang S, Li Q, Chen Q, Zhou Y, Park S, Lee G, et al. CancerLocator: non-invasive cancer
 diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA. Genome
 Biol. 2017;18(1):53.
- 58. Yusipov I, Bacalini MG, Kalyakulina A, Krivonosov M, Pirazzini C, Gensous N, et al.
 Age-related DNA methylation changes are sex-specific: a comprehensive assessment. Aging
 (Albany NY). 2020;12(23):24057-80.
- Field AE, Robertson NA, Wang T, Havas A, Ideker T, Adams PD. DNA Methylation
 Clocks in Aging: Categories, Causes, and Consequences. Mol Cell. 2018;71(6):882-95.
- 840 60. Nguyen THH, Lu YT, Le VH, Bui VQ, Nguyen LH, Pham NH, et al. Clinical validation
- of a ctDNA-Based Assay for Multi-Cancer Detection: An Interim Report from a Vietnamese

842 Longitudinal Prospective Cohort Study of 2795 Participants. Cancer Investigation.

843 2023;41(3):232-48.

844

846 List of abbreviations

MCED	Multi-cancer early detection
ТОО	tissue of origin
cfDNA	Circulating cell-free DNA
ctDNA	Circulating tumor DNA
SPOT-MAS	Screening for the Presence Of Tumor by DNA Methylation And Size
AUC	Area Under the Curve
TM	Targeted methylation
GWM	Genome-wide methylation
CNA	Copy number aberration
FLEN	Fragment length
EM	End motif
LB	Liquid Biopsy
LR	Logistic regression
RF	Random Forest
XGB	Extreme Gradient Boosting
DNN	Deep neural network
GCNN	Graph Convolutional Neural Network

- CRC Colorectal cancer
- ROC Receiver Operating Characteristic

847 **Declarations**

848 Ethics approval and consent to participate:

This study was approved by the Ethics Committee of the Medic Medical Center, University of Medicine and Pharmacy and Medical Genetics Institute, Ho Chi Minh city, Vietnam. Written informed consent was obtained from each participant in accordance with the Declaration of

852 Helsinki.

853 **Consent for publication:**

Not applicable.

855 Availability of data and materials:

856 Sequencing data will be deposited in a public portal database (NCBI SRA) upon acceptance and

are available on request from the corresponding author, LST. The data are not publicly available

- 858 due to ethical restrictions.
- 859 **Competing interests:**
- 860 The authors declare no conflict of interest.
- 861 **Funding:**
- 862 The study was funded by Gene Solutions
- 863 **Disclosure statement:**

- 864 The authors including LST, HNN, HG, MDP, HHN and DSN hold equity in Gene Solutions. The
- funder Gene Solutions provided support in the form of salaries for authors are inventors on the
- patent application (USPTO 17930705). We also confirm that this does not alter our adherence to
- 867 Cancer Investigation policies on sharing data and materials.

868 Author contribution:

- 869 Conceptualization: DLV, THP, TXJ, VCN, HTN, TVN, HG, HNN, MDP, LST
- 870 Patient consultancy and screening: DLV, THP, TXJ, VCN, HTN, TVN, QTD, TND, AMT,
- 871 VHN, VTAN, LMQH, QDT, TTTP, TDH, BTN, TNVN, TDN, DTBP, BHHP, TLV, THTN,
- 872 TTT, MHT, NCT, TKL, THTT, MLD, HPTB, VVK, TAP, DHT, TNAL, TVNP, MTL, DSN,
- 873 VTC, TTTD, HST
- 874 Formal analysis: VTCN, THN, NNTD, TMQP, TDN, THHN, LAKH, THT, DHV, TMTT,
- 875 MNN, TTVV, ANN, TTT, VUT, MPL, TTD, TVP, LHDN
- 876 Supervision: DKT
- 877 Writing-original draft: VTCN, GTHN, TTTT, LST
- 878 Writing-review and editing: VTCN, GTHN, TTTT, MDP, LST

879 Acknowledgments:

- 880 We thank all participants who agreed to take part in this study, and all the clinics and hospitals
- 881 who assisted in patient consultation and sample collection.

882

884 Figures and Tables



885

Figure 1. Workflow of SPOT-MAS assay for multi-cancer detection and localization. There
are three main steps in the SPOT-MAS assay. Firstly, cfDNA is isolated from peripheral blood,
then treated with bisulfite conversion and adapter ligation to make whole-genome bisulfite

889 cfDNA library. Secondly, whole-genome bisulfite cfDNA library is subjected to hybridization by 890 probes specific for 450 target regions to collect the target capture fraction. The whole-genome fraction was retrieved by collecting the 'flow-through' and hybridized with probes specific for 891 892 adapter sequences of DNA library. Both the target capture and whole-genome fractions were 893 subjected to massive parallel sequencing and the resulting data were pre-processed into five different features of cfDNA: Target methylation (TM), genome-wide methylation (GWM), 894 895 fragment length profile (Flen), DNA copy number (CNA) and end motif (EM). Finally, machine learning models and graph convolutional neural networks are adopted for classification of cancer 896 897 status and identification tissue of origin.



Figure 2. Analysis of targeted methylation in cfDNA. (A) Volcano plot shows log_2 fold change (logFC) and significance (-log₁₀ Benjamini-Hochberg adjusted p-value from Wilcoxon rank-sum test) of 450 target regions when comparing 499 cancer patients and 1,076 healthy controls in the discovery cohort. There are 402 DMRs (p-value < 0.05), color-coded by genomic locations. (B) Number of DMRs in the four genomic locations. (C) KEGG and WP pathway enrichment analysis using g:Profiler for genes associated with the DMRs. A total of 36 pathways are enriched, suggesting a link between differences in methylation regions and tumorigenesis.



Figure 3. Genome-wide methylation changes in cfDNA of cancer patients. (A) Density plot showing the distribution of genome-wide methylation ratio for all cancer patients (red curve, n =499) and healthy participants (blue curve, n = 1,076). The left-ward shift in cancer samples indicates global hypomethylation in the cancer genome (p < 0.0001, two-sample Kolmogorov-Smirnov test). (B) Log₂ fold change of methylation ratio between cancer patients and healthy participants in each bin across 22 chromosomes. Each dot indicates a bin, identified as hypermethylated (red), hypomethylated (blue), or no significant change in methylation (grey).



917

Figure 4. Analysis of copy number aberration (CNA) in cfDNA. (A) Log₂ fold change of DNA copy number in each bin across 22 autosomes between 499 cancer patients and 1,076 healthy participants in the discovery cohort. Each dot represents a bin identified as gain (red), loss (blue) or no change (grey) in copy number. (B) Proportions of different CNA bins in each autosomes.



Figure 5. Analysis of fragment length patterns of ctDNA in plasma. (A) Density plot of fragment length between cancer patients (red, n=499) and healthy participants (blue, n=1,076) in the discovery cohort. Inset corresponds to an x-axis expansion of short fragment (<150 bp). (B) Ratio of short to long fragments across 22 autosomes. Each dot indicates a mean ratio for each bin in cancer patients (red) and healthy participants (blue).



Figure 6. Differences in 4-mer end motif between cancer and healthy cfDNA. (A) Heatmap
shows log₂ fold change of 256 4-mer end motifs in cancer patients (n=499) compared to healthy
controls (n=1,076). (B) Box plots showing the top ten motifs with significant differences in
frequency between cancer patients (red) and healthy controls (blue) using Wilcoxon rank-sum
test with Bonferroni-adjusted p-value < 0.0001.



Figure 7. Model construction and performance validation for SPOT-MAS. (A) Two model 938 939 construction strategies for cancer detection. (B) and (C) ROC curves comparing the performance 940 of single-feature models, and two combination models (concatenate and ensemble stacking) in 941 the discovery (B) and validation cohorts (C). (D) and (E) Bar charts showing the specificity and sensitivity of single-feature models and two combination models (concatenate and ensemble 942 stacking) in the discovery (D) and validation cohorts (E). (F) and (G) Dot plots showing the 943 944 sensitivity of SPOT-MAS assay in detection of 5 different cancer types in the discovery (F) and 945 validation cohorts (G). The points and error bars represent the average sensitivity over 20 runs and 95% confidence intervals. Feature abbreviations as follows: TM - target methylation 946 density, GWM – genome-wide methylation density, CNA – copy number aberration, EM – 4-947 mer end motif, FLEN - fragment length distribution, LONG - long fragment count, SHORT -948 949 short fragment count, TOTAL – all fragment count, RATIO – ratio of short/long fragment.





Е



D



F

Validation



952 Figure 8. The performance of SPOT-MAS assay in prediction of the tissue of origin. (A)

- 953 Model construction strategy to predict tissue of origin by combining nine sets of cfDNA features
- using graph convolutional neural networks. (B) Heatmap shows feature important scores of five
- 955 cancer types. (C) Bar chart indicates the contribution of important features for classifying five
- 956 different cancers. (D) Three dimensions graph represents the classification of five cancer types.
- 957 (E) and (F) Cross-tables show agreement between the prediction (x-axis) and the reference (y-
- axis) to predict tissue of origin in the discovery cohort (E) and validation cohort (F).

Table 1. Summary of clinical features of 738 cancer patients and 1,550 healthy controls in

961 discovery and validation cohorts.

Clinical features		Discovery cohort (N=1,575)					Validation cohort (N=713)					
		Cancerfeatures(N = 499)		Healthy (N = 1,076)		p-value (Cancer	Cancer (N = 239)		Healthy (N = 474)		p-value	
											(Cancer	
		N	Percentage	N	Percentage	vs Healthy)	N	Percentage	N	Percentage	vs Healthy)	
Gender	Female	279	55.9%	599	55.7%	0.0281#	126	52.72%	270	56.1%	0.2818#	
	Male	220	44.1%	477	44.3%	0.9281	113	47.28%	204	43.9%		
	Median	58		47		< 0.0001	59		48		< 0.0001	
Age	Min	25		18		##	28		19		##	
	Max	97		84			92		85			
	Ι	52	10.4%				23	9.6%				
	II	169	33.9%				69	28.9%				
	IIIA	150	30.1%				77	32.2%				
Stage	Non-										0.4947#	
0	with	128	25.7%				70	29.3%				
	unknown											
	staging											
	information											



[#] P-values from Chi-square test; ^{##} P-values from Mann-Whitney test